Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.


The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by Reaxense.


The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.


We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.


Several key aspects differentiate our library:


  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.

  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.

  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.

  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.


PARTNER
Receptor.AI
 
UPACC
A6NHC0

UPID:
CAN8_HUMAN

ALTERNATIVE NAMES:
New calpain 2; Stomach-specific M-type calpain

ALTERNATIVE UPACC:
A6NHC0; B2RXL2

BACKGROUND:
Calpain-8, identified as Stomach-specific M-type calpain and New calpain 2, is integral to calcium-regulated non-lysosomal thiol-protease activity. It is implicated in the regulation of membrane trafficking in gastric surface mucus cells, facilitating the movement of mucus cells via interactions with coat protein. Additionally, Calpain-8 is responsible for the cleavage of the coatomer complex's beta-subunit, underscoring its pivotal role in cellular trafficking mechanisms.

THERAPEUTIC SIGNIFICANCE:
Exploring the functions of Calpain-8 offers a pathway to uncovering novel therapeutic approaches. Its critical role in the regulation of membrane dynamics and proteolytic activities within the stomach's mucus cells presents a unique opportunity for targeting gastrointestinal disorders.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.